Skip to main content
  • Recurv Pharma Inc.
  • Investment: 2023
  • Status: Active

Recurv is a U.S.-based special purpose biotechnology company created to develop to clinical proof-of-concept one oncology compound, RP-001, a novel taxane therapy to treat solid tumors.
The project is fully financed by TVM Life Science Innovation II. In various pre-clinical oncology models, the asset has shown strong efficacy data in addition to a potentially superior safety profile
compared to currently available taxanes, as well as synergistic effects with immune checkpoint inhibitors.

Involved Team

Dr. Luc Marengère
Managing Partner
Dr. Valentina Agostoni
Senior Associate,

James E. Egan (CEO)